The complaint centers on claims that Phreesia violated the Securities Exchange Act of 1934 by issuing false and misleading statements to shareholders. Specifically, the firm asserts that the company touted its Network Solutions segment as a primary growth driver while masking underlying uncertainties that threatened revenue targets. These optimistic projections reportedly crumbled when the market learned the truth, resulting in financial losses for investors.
In section Releases
Schall Law Firm Targets Phreesia Over Alleged Securities Fraud
Investors who purchased Phreesia, Inc. stock between May 8, 2025, and March 30, 2026, are being urged to join a class action lawsuit. The Schall Law Firm alleges the company misled the market regarding its fiscal year 2027 growth projections and the stability of its pharmaceutical marketing commitments.
Attorney Brian Schall is currently soliciting participants for the litigation, which focuses on the period spanning May 2025 through late March 2026. Shareholders looking to discuss their legal standing or potential recovery options have until July 13, 2026, to reach out to the Los Angeles-based firm. As the class has not yet been certified, those who do not step forward remain absent class members without formal legal representation.
Comments (0)
No comments yet. Be the first!